Context Therapeutics Inc. - Common Stock (CNTX)
CUSIP: 21077P108
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 91,741,639
- Total 13F shares
- 65,197,080
- Share change
- -3,770,886
- Total reported value
- $95,840,638
- Price per share
- $1.47
- Number of holders
- 42
- Value change
- -$5,288,639
- Number of buys
- 16
- Number of sells
- 12
Quarterly Holders Quick Answers
What is CUSIP 21077P108?
CUSIP 21077P108 identifies CNTX - Context Therapeutics Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21077P108:
Top shareholders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MPM BioImpact LLC |
13D/G
13F
|
Company |
12%
|
10,679,391
|
$15,698,705 | -$5,918,942 | 31 Dec 2025 | |
| Avidity Partners Management LP |
13F
|
Company |
9.8%
|
8,981,855
|
$8,701,621 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
8.3%
|
7,419,355
|
$7,419,355 | $0 | 31 Mar 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
8.1%
|
7,419,355
|
$7,187,871 | — | 30 Sep 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
8.1%
|
7,407,906
|
$7,176,779 | — | 30 Sep 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
5.1%
|
4,683,711
|
$4,537,579 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13D/G
13F
|
Company |
4.5%
|
4,003,380
|
$4,003,380 | $0 | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
3,495,031
|
$3,386,685 | — | 30 Sep 2025 | |
| Blackstone Inc. |
13F
|
Company |
2.7%
|
2,440,330
|
$2,364,680 | — | 30 Sep 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
1.8%
|
1,663,355
|
$1,611,458 | — | 30 Sep 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.8%
|
1,661,950
|
$1,610,097 | — | 30 Sep 2025 | |
| Martin A. Lehr |
13D/G
|
Martin Lehr |
2.1%
|
1,595,742
|
$1,595,742 | $0 | 31 Dec 2024 | |
| Sio Capital Management, LLC |
13F
|
Company |
1.5%
|
1,341,636
|
$1,299,777 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.93%
|
848,970
|
$822,482 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.66%
|
608,577
|
$589,897 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.44%
|
402,653
|
$390,090 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.38%
|
351,094
|
$340,140 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.35%
|
320,127
|
$310,139 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.17%
|
152,607
|
$147,846 | — | 30 Sep 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.14%
|
132,786
|
$128,643 | — | 30 Sep 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.14%
|
125,852
|
$121,925 | — | 30 Sep 2025 | |
| Pathstone Holdings, LLC |
13F
|
Company |
0.12%
|
110,244
|
$106,804 | — | 30 Sep 2025 | |
| Mill Creek Capital Advisors, LLC |
13F
|
Company |
0.11%
|
104,631
|
$101,367 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.11%
|
103,363
|
$100,138 | — | 30 Sep 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.11%
|
100,000
|
$96,880 | — | 30 Sep 2025 | |
| Clear Harbor Asset Management, LLC |
13F
|
Company |
0.1%
|
92,804
|
$89,909 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.09%
|
82,111
|
$79,549 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.07%
|
66,384
|
$64,313 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.04%
|
35,750
|
$34,678 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.03%
|
25,500
|
$24,616 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.02%
|
21,967
|
$21,282 | — | 30 Sep 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.02%
|
20,000
|
$19,376 | — | 30 Sep 2025 | |
| CAXTON CORP |
13F
|
Company |
0.02%
|
18,403
|
$17,829 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.01%
|
10,597
|
$10,266 | — | 30 Sep 2025 | |
| Tarek Sahmoud |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
35,000
mixed-class rows
|
$8,415 | — | 16 Aug 2022 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
7,382
|
$7,153 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
434
|
$420 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
167
|
$162 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
117
|
$113 | — | 30 Sep 2025 | |
| Ullmann Claudio Dansky |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
174,960
|
— | — | 13 Feb 2025 | |
| Andy Pasternak |
3/4/5
|
Director |
—
class O/S missing
|
138,900
|
— | — | 12 Jun 2025 | |
| Jennifer Evans Stacey |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Karen L. Smith |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Linda West |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Luke Nathaniel Walker |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Philip W. Kantoff |
3/4/5
|
Director |
—
class O/S missing
|
123,500
|
— | — | 12 Jun 2025 | |
| Richard J. Berman |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 13 Jun 2024 | |
| Evan G. Dick |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
29,223
|
— | — | 15 Feb 2022 | |
| William F. Rencher |
3/4/5
|
Former Section 16 officer |
—
class O/S missing
|
8,000
|
— | — | 15 Feb 2022 |
Institutional Holders of Context Therapeutics Inc. - Common Stock (CNTX) as of Q4 2025
As of 31 Dec 2025,
Context Therapeutics Inc. - Common Stock (CNTX) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,197,080 shares.
The largest 10 holders included
MPM BIOIMPACT LLC, Blue Owl Capital Holdings LP, Deep Track Capital, LP, Nextech Invest, Ltd., Avidity Partners Management LP, GREAT POINT PARTNERS LLC, FRANKLIN RESOURCES INC, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, and MARSHALL WACE, LLP.
This page lists
42
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
37
Q4 2025 holders
42
Holder diff
5
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.